This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
EPIRUS Biopharmaceuticals, Inc.
Drug Names(s): CRx-102
Description: BioMedTracker has two drug profiles for CRx-102. Please also see the once-daily formulation, Synavive AR.
CRx-102 is a novel orally available syncretic drug containing a low dose of the steroid prednisolone with dipyridamole. Dipyridamole may inhibit red blood cell uptake of adenosine, phosphodiesterase, and thromboxane A2 formation. Preclinical data suggest that when administered together in CRx-102, dipyridamole synergistically increases the immuno-modulatory activity of the reduced-dose prednisolone without a comparable increase in its adverse side effects.
Epirus and Zalicus
In April 2014, Epirus and Zalicus announced that they have entered into a definitive agreement under which Epirus will merge with Zalicus in an all-stock transaction. Following closing, Zalicus will be re-named Epirus Biopharmaceuticals.
In July 2014, EPIRUS Biopharmaceuticals announced the completion of a merger with Zalicus. The combined company, which has been renamed EPIRUS Biopharmaceuticals, will focus on the business of EPIRUS and operate under the leadership of the EPIRUS management team.
Pink Sheet Synavant
Additional information available to subscribers only: